Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Cadrenal Therapeutics, Inc. (CVKD) had Stock-Based Compensation of $0.55M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-3.85M |
|
-- |
|
-- |
|
$3.93M |
|
$-3.93M |
|
$0.08M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.93M |
|
$-3.92M |
|
1.84M |
|
1.84M |
|
$-2.09 |
|
$-2.09 |
|
| Balance Sheet Financials | |
$7.94M |
|
$0.00M |
|
$0.01M |
|
$7.95M |
|
$1.84M |
|
-- |
|
-- |
|
$1.84M |
|
$6.11M |
|
$6.11M |
|
$6.11M |
|
1.91M |
|
| Cash Flow Statement Financials | |
$-4.65M |
|
$-0.00M |
|
$1.97M |
|
$10.02M |
|
$7.34M |
|
$-2.68M |
|
|
Stock-Based Compensation |
$0.55M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.65M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-62.90% |
|
-62.90% |
|
-48.35% |
|
-62.90% |
|
$3.20 |
|
$-2.52 |
|
$-2.52 |
|